Company / PP&E (Net)
Catalyst Pharmaceuticals Partners, Inc. PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$1.0M
FY2025
5-year range
$847.0K / $1.4M
FY2021-FY2025
Trend
-23.4%
vs FY2024
Sector context
#160 of 195
Health Care
What the data says
Catalyst Pharmaceuticals Partners, Inc.'s pp&e (net) of $1M is lower than 82% of companies in the Health Care sector (FY2025). PP&E (Net) has fluctuated over the past 10 years, ranging from $130,000 in FY2020 to $1M in FY2024.
Based on SEC 10-K filings.
$1M in FY2025 with a 5-year CAGR of +51.5%.
Declined from $1M to $1M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +7.0%
- 5-Year CAGR
- +51.5%
- 10-Year CAGR
- -
Sector benchmark
Bottom 18% in Health CareTop 82% of 195This company $1.0M Sector average $771.3M
▼
-99.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +51.5%, indicating consistent growth.
- In FY2025, pp&e (net) decreased 23.4% year-over-year.
- Ranks #160 out of 195 companies in the Health Care sector.
- Peak pp&e (net) was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 4.78 (safe zone, above 2.9 threshold)
- Strong profit margin: 33.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.0M | -23.4% |
| FY2024 | $1.4M | +13.3% |
| FY2023 | $1.2M | +41.1% |
| FY2022 | $847.0K | -11.7% |
| FY2021 | $959.0K | +637.7% |
| FY2020 | $130.0K | -38.2% |
| FY2019 | $210.5K | -14.2% |
| FY2018 | $245.4K | +28.2% |
| FY2017 | $191.4K | -21.6% |
| FY2016 | $244.2K | +27.5% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026